Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Gene Therapy.

Vancouver Cancer Centre, Vancouver, British Columbia, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Vancouver, British Columbia
Treatments:Chemotherapy, Gene TherapyHospital:Vancouver Cancer Centre
Drugs:Journal:Link
Date:Dec 2001

Description:

Patients: This Phase I dose-finding study involved 26 patients with metastatic hormone-refractory prostate cancer. The median age was 69 and the median PSA was 135 (ranged from 30-860). Sites of metastasis included bone and lymph nodes.

Treatment: The treatment consisted of gene therapy – Genasense, an antisense Bcl-2 oligonucleotide and chemotherapy – mitoxantrone (novantrone). (Genasense or Bcl-2 is thought to be a negative prognostic indicator in prostate cancer and antisense specific to this gene should inhibit its expression.)

Toxicity: Toxicities included neutropenia (grade 3 or 4), thrombocytopenia (grade 2), lymphopenia (grade 3), elevated creatinine (grade 1-2), fever (grade 1-2), and vomiting/diarrhea (grade 2)

Results: Median overall survival was 18.7 months.

Support: The study was supported in part by Genta. Genta markets Genasense.

Correspondence: Kim Chi, MD




Back